The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Smoldering myeloma treatment landscape & MRD negativity
The best chance to acheive measurable residual disease (MRD) negativity is to treat in the smoldering stage of multiple myeloma (MM), as discussed here by Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands. Dr Broyl covers what the data indicate for the treatment of this population. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
